Startseite Kongressberichte 2020 ESMO VIRTUAL 2020 SARS-CoV-2 & Cancer Proffered Paper - SARS-CoV-2 and cancer 2

Proffered Paper - SARS-CoV-2 and cancer 2

LINK to Proffered Paper - SARS-CoV-2 and cancer 2

LINK to STREAM (needs an ESMO registration)

LBA72 - Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19)

The abstract concludes: We confirmed a priori identified risk factors for poor prognosis in the largest COVID-19/cancer cohort and performed initial analysis of lab parameters, informing risk assessment.




LBA73 - The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01

The abstract concludes: Our data suggest that part of the ORF1ab encodes multiple CD8 T cell antigens including one immunodominant epitope. Noteworthy these epitopes were derived from a part of the viral genome that is not included in the majority of vaccine candidates in development, and this may potentially influence their clinical activity and safety profile.


LBA74 - Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)

The abstract concludes: Significant disruptions to routine cancer care were observed during the pandemic period relative to the prior 3 months. Racial and ethnic barriers to the adoption of telehealth, and related socioeconomic factors, place these vulnerable populations simultaneously at disproportionate risk for decreased cancer-related visits and COVID infection, thereby exacerbating existing racial and ethnic health disparities.


LBA75 - Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)

The abstract concludes: Facing this ongoing global pandemic, TERAVOLT is the largest thoracic malignancy database confirming the high risk for COVID-19 mortality in this specific patient group. Physicians need to evaluate the risk of mortality from COVID-19 based on age, smoking status, stage of cancer, performance status, need for steroids and specific therapy in order to determine the appropriateness for cancer therapy and tailor patient care taking into account patients’ wishes and status of pandemic in the country.